Worldwide, cancer is a leading cause of death and is characterized by the uncontrolled growth of abnormal cells that have the ability to evade the immune system. Our late stage pipeline includes various TCR T-cell therapies in clinical trials across multiple solid tumors.
Afamitresgene autoleucel or “afami-cel” is our first-generation TCR T-cell therapy targeting MAGE-A4. We began rolling submission of a BLA for afami-cel for the treatment of people with synovial sarcoma in late 2022 and aim to complete the submission in Q4 2023. We are also developing next-generation cell therapies with ADP-A2M4CD8 being evaluated in the SURPASS family of trials.
Adaptimmune is developing an industry-leading TCR T-cell therapy pipeline in solid tumors, and has a deep pipeline of identified and proprietary targets for further product development.